

Indication	<p>Maintenance monotherapy treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy.</p> <p>NB The patient should commence maintenance niraparib within 12 weeks from the date of the first day of the last cycle of 1st line chemotherapy and have received a minimum of 4 cycles of platinum-based treatment. In the PRIMA clinical trial subjects received ≥ 6 and ≤ 9 cycles of platinum-based therapy.</p> <p>The patient must have not previously received any PARP inhibitor except in these circumstances:</p> <p>Patients who HAVE a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation can have received niraparib as part of an early access scheme for this indication or 1st line maintenance olaparib if it has had to be stopped within 3 months of its start solely as a consequence of dose-limiting toxicity and in the clear absence of disease progression.</p> <p>Patients who DO NOT HAVE a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation can have received 1st line maintenance rucaparib which has had to be stopped within 3 months of its start solely as a consequence of dose-limiting toxicity and in the clear absence of disease progression.</p>
Treatment Intent	Palliative (maintenance)
Frequency and number of cycles	<p>Repeat every 28 days</p> <p>Continuous until disease progression or unacceptable toxicity or patient choice.</p> <p>NB: NICE heard evidence during the niraparib appraisal that clinicians would wish to discuss with patients in continued complete remission when it would be an appropriate time to discontinue maintenance niraparib therapy and that this time was likely to be after approximately 3 years of maintenance treatment</p> <p>NB: A formal medical review as to whether maintenance treatment with niraparib should continue or not will be scheduled to occur at least by the start of the third cycle of treatment.</p>
Monitoring parameters pre-treatment	<ul style="list-style-type: none"> • Virology screening: All new patients referred for systemic anti-cancer treatment should be screened for hepatitis B and C and the result reviewed prior to the start of treatment. Patients not previously tested who are starting a new line of treatment, should also be screened for hepatitis B and C. Further virology screening will be performed following individual risk assessment and clinician discretion. • Monitor FBC at baseline and every week during cycle 1, thereafter FBC prior to each of cycles 2-11 or more frequently if clinically indicated. Thereafter as clinically indicated. • U&Es and LFTs prior to each cycle. • Monitor BP at baseline and weekly for the first 2 cycles, then prior to each cycle for the next 10 cycles then as clinically indicated. Hypertension should be adequately controlled before starting niraparib. Niraparib should be discontinued if hypertension cannot be adequately controlled.

Protocol No	GYN-043	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	5	Written by	M. Archer
Supersedes version	4	Checked by	C. Waters V3/V4/V5 E. Parry V2 V3 updated following formulation change only V4 & V5 updated in line with commissioning criteria change
Date	07.05.2025	Authorising consultant (usually NOG Chair)	R. Jyothirmayi V2

	<ul style="list-style-type: none"> • Adverse reactions: See tables 1 and 2 below. Treatment should be interrupted (but for no longer than 28 consecutive days) to allow the patient to recover from the adverse reaction and then restart at the same dose (unless otherwise stated in tables below). In the case that the adverse reaction recurs, it is recommended to interrupt treatment and then to reduce the dose. If adverse reactions persist beyond a 28-day dose interruption, or interruption with dose reduction are insufficient to manage adverse reactions, discontinue niraparib. • Dose reductions: <u>Starting dose level 200mg</u>, 1st dose reduction should be to 100mg OD, no further dose reduction recommended and treatment should be discontinued. <u>Starting dose level 300mg</u>, 1st dose reduction should be to 200mg OD, and 2nd dose reduction to 100mg OD. No further dose reduction recommended and treatment should be discontinued. • Renal impairment: No dose adjustment for patients with mild to moderate renal impairment. Use with caution in patients with severe renal impairment or end stage renal disease undergoing haemodialysis, no data available. • Hepatic impairment: No dose adjustment is needed in patients with mild hepatic impairment. In moderate hepatic impairment (any AST and TB > 1.5 x - 3 x ULN) the recommended starting dose is 200mg once daily. Use with caution in patients with severe hepatic impairment, no data available. • Common drug interactions (for comprehensive list refer to BNF/SPC): Anticoagulants and drugs that reduce the platelet count should be used with caution. Interaction is unlikely but give with caution with drugs metabolised by CYP3A4 particularly if they have a narrow therapeutic range (e.g. ciclosporin, tacrolimus, alfentanil), drugs metabolised by CYP1A2 particularly if they have a narrow therapeutic range (e.g. clozapine, theophylline), substrates of BCRP (e.g. simvastatin, methotrexate, atorvastatin) and substances that undergo an uptake transport by OCT1 such as metformin. • Posterior Reversible Encephalopathy Syndrome (PRES): has been reported in patients receiving niraparib. In patients developing suspected or confirmed PRES, treatment should be discontinued. • Missed doses: If a patient misses a dose, take next dose at usual time. • Driving & using machines: Caution, niraparib may cause asthenia, fatigue, dizziness or difficulties concentrating.
Reference(s)	SPC accessed online 13.08.2024 KMCC protocol GYN-043 V3 CDF list accessed online V1.318

NB For funding information; refer to CDF and NICE Drugs Funding List

Protocol No	GYN-043	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	5	Written by	M. Archer
Supersedes version	4	Checked by	C. Waters V3/V4/V5 E. Parry V2 V3 updated following formulation change only V4 & V5 updated in line with commissioning criteria change
Date	07.05.2025	Authorising consultant (usually NOG Chair)	R. Jyothirmayi V2

Table 1: Dose modifications for non-haematologic adverse reactions

≥ Grade 3 where prophylaxis is not considered feasible or adverse reaction persists despite treatment	First occurrence: Withhold niraparib for a maximum of 28 days or until resolution of adverse reaction. Resume niraparib at a reduced dose level.
	Second occurrence: Withhold niraparib for a maximum of 28 days or until resolution of adverse reaction. Resume niraparib at a reduced dose or discontinue.
≥ Grade 3 adverse reaction lasting more than 28 days while patient is administered niraparib 100 mg/day	Discontinue treatment.

Table 2: Dose modifications for haematologic adverse reactions

Haematologic adverse reaction requiring transfusion or haematopoietic growth factor support	For patients with platelet count $\leq 10 \times 10^9/L$ platelet transfusion should be considered. If there are other risk factors for bleeding such as co-administration of anticoagulation or antiplatelet medicinal products, consider interrupting these substances and/or transfusion at a higher platelet count. Resume niraparib at a reduced dose.
Platelet count $< 100 \times 10^9/L$	First occurrence: Withhold niraparib for a maximum of 28 days and monitor blood counts weekly until platelet counts return to $\geq 100 \times 10^9/L$ Resume Niraparib at same or reduced dose based on clinical evaluation. If platelet count is $< 75 \times 10^9/L$ at any time, resume at a reduced dose.
	Second occurrence: Withhold niraparib for a maximum of 28 days and monitor blood counts weekly until platelet counts return to $\geq 100 \times 10^9/L$ Resume niraparib at a reduced dose. Discontinue niraparib if the platelet count has not returned to acceptable levels within 28 days of the dose interruption period, or if the patient has already undergone dose reduction to 100 mg each day.
Neutrophil $< 1 \times 10^9/L$ or Haemoglobin $< 80g/L$	Withhold niraparib for a maximum of 28 days and monitor blood counts weekly until neutrophil counts return to $\geq 1.5 \times 10^9/L$ or haemoglobin returns to $\geq 90 g/L$. Resume niraparib at a reduced dose. Discontinue niraparib if neutrophils and/or haemoglobin have not returned to acceptable levels within 28 days of the dose interruption period, or if the patient has already undergone dose reduction to 100 mg each day.
Confirmed diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML)	Permanently discontinue niraparib.

Protocol No	GYN-043	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	5	Written by	M. Archer
Supersedes version	4	Checked by	C. Waters V3/V4/V5 E. Parry V2 V3 updated following formulation change only V4 & V5 updated in line with commissioning criteria change
Date	07.05.2025	Authorising consultant (usually NOG Chair)	R. Jyothirmayi V2

Repeat every 28 days

TTO	Drug	Dose	Route	Directions
Day 1	NIRAPARIB	200mg*	PO	<p>Swallow whole once daily with water at the same time each day, preferably at night.</p> <p>Take without food (at least 1 hour before or 2 hours after a meal) or with a light meal.</p> <p>Do not crush or chew.</p> <p>Available as 100mg tablets.</p>
	Metoclopramide	10mg	PO	<p>Up to 3 times a day as required.</p> <p>Do not take for more than 5 days continuously.</p>
	*The recommended starting dose is 200mg OD, however for patients who weigh ≥ 77 kg and have baseline platelet count $\geq 150 \times 10^9/L$, the recommended starting dose is 300mg OD.			

Protocol No	GYN-043	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	5	Written by	M. Archer
Supersedes version	4	Checked by	C. Waters V3/V4/V5 E. Parry V2 V3 updated following formulation change only V4 & V5 updated in line with commissioning criteria change
Date	07.05.2025	Authorising consultant (usually NOG Chair)	R. Jyothirmayi V2